Group 1 - The core point of the article highlights that Touyun Biotech (01332) experienced a significant stock price increase, rising over 80% during the trading session, with a current increase of 54.47% to HKD 0.38, and a trading volume of HKD 12.0568 million [1] - Recently, Touyun Biotech announced a strategic cooperation agreement involving its wholly-owned subsidiary, Shanxi Touyun, which will procure no less than RMB 1 billion worth of Rhodella and related products from a sales consortium during the period from 2026 to 2028 [1] - The company’s Rhodella product received a new usage license from the National Health Commission in November 2024, expanding its application range and entering markets for artificial fish, shrimp, and plant-based milk [1]
港股异动 | 透云生物(01332)盘中涨超80% 山西透云近期签约10亿元莱茵衣藻产品订单